ImStar Therapeutics

ImStar Therapeutics

ImStar Therapeutics is company developing treatments for ALS, dementia, and other neurodegenerative diseases.

All edits by  Meredith Hanel 

Edits on 14 Oct, 2019
Meredith Hanel
Meredith Hanel edited on 14 Oct, 2019
Edits made to:
Article (+1243/-400 characters)
Article

ImStar Therapeutics is a biotechnology company developing treatments for neurodegenerative diseases. The company is headquartered in Vancouver, British Columbia, Canada and was founded in 2012 by Daniel Wattier and Jean Pierre Julien, Professor and Senior Canada Research Chair at Université Laval. ImStar Therapeutics is developing treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Dementia, Alzheimer's Disease, and Parkinson's Disease.

...

ImStar Therapeutics is developing treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS), Dementia, Alzheimer's Disease, and Parkinson's Disease. The company is using its unique research findings and understanding of a protein called TAR DNA-binding protein 43 (TDP-43) and its role in inflammatory responses to develop novel treatments for neurodegenerative diseases.

Pipeline

The company is using its unique research findings and understanding of a protein called TAR DNA-binding protein 43 (TDP-43) and its role in inflammatory responses to develop novel treatments for neurodegenerative diseases. The ALS therapeutic target TDP-43, also called TANA (TDP-43 Associated NF-κB Activation) is based on the research of Dr. Julien at Université Laval.

IMS-088 was considered their lead drug development program in 2016. The compound was designed to target a key immune system activation pathway involved in neurodegeneration. IMS-088 was derived from withaferin A, a natural compound isolated from the leaves of the winter cherry plant Withania somnifera. Withaferin A in preclinical studies showed improvements in function and extended survival but lacked certain characteristics that would make it optimal for drug development. The compound IMS-088 was designed by ImStar chemists to have improved drug-like properties and to be potent and safe in preclinical studies.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.